Filtered By:
Specialty: Cancer & Oncology
Drug: Docetaxel
This page shows you your search results in order of date.
Order by Relevance | Date
Total 73 results found since Jan 2013.
Androgen receptor knockdown enhances prostate cancer chemosensitivity by down ‐regulating FEN1 through the ERK/ELK1 signalling pathway
ConclusionCollectively, our studies demonstrate that AR knockdown improves the DTX sensitivity of prostate cancer cells by downregulating FEN1 through the ERK/ELK1 signalling pathway.
Source: Cancer Medicine - June 16, 2023 Category: Cancer & Oncology Authors: Weijie Xie,
Shulin Li,
Huan Guo,
Jiawei Zhang,
Menjiang Tu,
Rui Wang,
Bingling Lin,
Yuqi Wu,
Xiangwei Wang Tags: RESEARCH ARTICLE Source Type: research
Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer
We examined paired tissues from Taiwanese patients and observed that 65.09% and 68.25% of patients exhibited TSTD1 hypomethylation and overexpression, respectively. A significant correlation was found between TSTD1 hypomethylation and overexpression in Taiwanese (74.2%, p = 0.040) and Western (88.0%, p < 0.001) cohorts. High expression of TSTD1 protein was observed in 68.8% of Taiwanese and Korean breast cancer patients. Overexpression of TSTD1 in tumors of breast cancer patients was significantly associated with poor 5-year overall survival (p = 0.021) and poor chemotherapy response (p = 0.008). T47D cells treated with...
Source: Frontiers in Oncology - November 7, 2022 Category: Cancer & Oncology Source Type: research
Knockdown of USP8 inhibits prostate cancer cell growth, proliferation, and metastasis and promotes docetaxel ’s activity by suppressing the NF-kB signaling pathway
Ubiquitin-specific protease 8 (USP8) has been recently reported to be involved in tumorigenesis. Prostate cancer (PCa) is the most diagnosed malignancy among men, but USP8’s role in PCa is not yet investigated comprehensively. Therefore, the PCa cell lines DU145 and PC3 were transfected with USP8 siRNA or overexpressing vector together with or without docetaxel. The silencing USP8 and docetaxel treatment reduced cell viability and migration and promoted apoptosis. In contrast, USP8 knockdown was found to enhance docetaxel antitumor activity. In contrast, increased cell viability and migration were noticed upon USP8 overe...
Source: Frontiers in Oncology - October 20, 2022 Category: Cancer & Oncology Source Type: research
Decreased Expression of HN1 Sensitizes Prostate Cancer Cells to Apoptosis Induced by Docetaxel and 2-Methoxyestradiol
CONCLUSION: HN1 is an anti-apoptotic molecule and inhibits Docetaxel and 2-Methoxyestradiol induced apoptosis by targeting Cyclin B1.PMID:35414498
Source: Clinical Prostate Cancer - April 13, 2022 Category: Cancer & Oncology Authors: Lokman Varisli Source Type: research
Cancers, Vol. 14, Pages 1877: The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers
s
Borhane Annabi
Sortilin (SORT1) receptor-mediated endocytosis functions were exploited for this new approach for effective and safe treatments of gynecological cancers. Here, high expression of SORT1 was found in &gt;75% of the clinically annotated ovarian and endometrial tumors analyzed by immunohistochemistry. Therefore, the anticancer properties of the peptide-drug conjugate TH1902, a peptide that targets SORT1 and which is linked to docetaxel molecules, were investigated both in vitro using ovarian and endometrial cancer cell cultures and in vivo using xenograft models. In vitro, TH1902 inhibited cell p...
Source: Cancers - April 8, 2022 Category: Cancer & Oncology Authors: Jean-Christophe Currie Michel Demeule Cyndia Charfi Alain Zgheib Alain Larocque Bogdan Alexandru Danalache Amira Ouanouki Richard B éliveau Christian Marsolais Borhane Annabi Tags: Article Source Type: research
Overexpression of claspin promotes docetaxel resistance and is associated with prostate ‐specific antigen recurrence in prostate cancer
Claspin overexpression was related to poor PSA relapse-free prognosis. Claspin knockdown significantly upregulated the sensitivity to docetaxel in DU145 docetaxel-resistant cells. AbstractAlthough docetaxel (DTX) confers significant survival benefits in patients with castration-resistant prostate cancer (CRPC), resistance to DTX inevitably occurs. Therefore, clarifying the mechanisms of DTX resistance may improve survival in patients with CRPC. Claspin plays a pivotal role in DNA replication stress and damage responses and is an essential regulator for the S-phase checkpoint.CLSPN is an oncogenic gene that contributes to t...
Source: Cancer Medicine - July 9, 2021 Category: Cancer & Oncology Authors: Takashi Babasaki,
Kazuhiro Sentani,
Yohei Sekino,
Go Kobayashi,
Quoc Thang Pham,
Narutaka Katsuya,
Shintaro Akabane,
Daiki Taniyama,
Tetsutaro Hayashi,
Masaki Shiota,
Naohide Oue,
Jun Teishima,
Akio Matsubara,
Wataru Yasui Tags: ORIGINAL RESEARCH Source Type: research
Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis
CONCLUSIONS: In prostate cancer cells, DRG2 regulates G2/M arrest after docetaxel treatment. In prostate cancer cells with DRG2 knockdown, apoptosis increases without G2/M arrest in response to docetaxel treatment. These results show that inhibition of DRG2 expression can be useful to enhance docetaxel-induced apoptosis despite low-dose administration in castration-resistant prostate cancer.PMID:34190439 | DOI:10.4111/icu.20200574
Source: Clinical Prostate Cancer - June 30, 2021 Category: Cancer & Oncology Authors: Seong Cheol Kim Won Hyeok Lee Song Hee Kim Abdumadjidov Alisher Abdulkhayevich Jeong Woo Park Young Min Kim Kyung Hyun Moon Sang Hun Lee Sungchan Park Source Type: research
MicroRNA-224 modulates chemosensitivity of breast cancer cells to docetaxel by apoptosis inhibitor 5
CONCLUSION: An inverse association between miR-224 and API-5 in breast cancer cells was revealed. Dysregulation of miR-224 plays a vital role in the acquired DOC resistance of breast cancer and at least partially via targeting API-5.PMID:34076992
Source: Journal of B.U.ON. - June 2, 2021 Category: Cancer & Oncology Authors: Junying Zhang Ya Lu Ye Zhang Yan Chen Wenbo Zhu Hangju Zhu Jianzhong Wu Jinhai Tang Source Type: research
